IonStar could upend industry standards, and quicken medical diagnosis and drug development
A new protein analysis tool developed at the University at Buffalo could vastly increase the speed and precision with which disease and drug effects are analyzed.
The groundbreaking tool, called IonStar, is the first to provide near-perfect accuracy when quantifying and comparing the abundance of proteins in the bodies of people who are healthy and ill.
Compared to industry standard MaxQuant, IonStar improved the measurement consistency of proteins in low abundance and lowered the amount of missing data in results from 17 percent to 0.1 percent, a level that has never been achieved with large samples.
The new tool could increase the quality and accuracy of medical diagnosis and quicken the pace of pharmaceutical development.
“IonStar will totally change the face of clinical and pharmaceutical research and industry, where large investigations are often critical,” says Jun Qu, PhD, lead investigator and professor in the UB School of Pharmacy and Pharmaceutical Sciences.
The research was published yesterday in the Proceedings of the National Academy of Sciences (PNAS).
Playing spot the difference
The abundance of proteins in the body that correspond with disease or pharmaceutical reactions can provide researchers with vital clues for accurately diagnosing a condition, and for developing potential therapies and evaluating drug effects.
Protein analysis tools are used to quantify and compare the abundance of proteins in groups of healthy individuals with those who are ill or treated with a drug. Changes in protein abundances, when analyzed together, often reveal novel biomarkers.
The challenge for researchers is that current tools are not efficient at analyzing large numbers of samples. One type of method, the labeling-method, uses chemical tags to label proteins. The issue: The software can only analyze up to 10 samples at a time, making it difficult for researchers to conduct typical pharmaceutical and clinical studies, says Qu.
The alternative, the label-free method, can analyze a large number of samples at once at the expense of accuracy and precision, causing researchers to waste time and resources validating falsely identified biomarkers.
IonStar increases accuracy and precision and lowers missing data by improving on sample preparation methods, alignment and feature detection designs for mass spectrometry analysis.
“For example, in clinical trials, comparing a handful of patients gets you nowhere,” says Qu. “If you can analyze a large number of patients with high-quality data, you can discover and track biomarkers much more accurately and reliably. The same is true for pharmaceutical investigations.”
Proving the concept in traumatic brain injury
Researchers used IonStar to quantify proteins in rats with traumatic brain injury, a debilitating condition that accounts for 2.2 million emergency room visits annually in the United States.
Using 100 tissue samples, IonStar identified 7,000 proteins, including 1,000 that differed in abundance, without missing data.
IonStar also measured low-abundance proteins with higher accuracy and precision than other prevalent analysis tools. This capability is critical, says Qu, because proteins that appear in smaller amounts play a more influential role in the body.
“If higher-level proteins are soldiers, then lower-level proteins are the commanders. They are the regulators that tell the higher-level proteins what to do,” says Qu.
Qu has used IonStar and similar techniques to analyze protein variation in cancer, diabetes, cardiovascular disease, neurodegeneration and retina degeneration as well.
Future work on IonStar will focus on expanding the number of samples the tool can analyze.
The Latest on: Drug development
via Google News
The Latest on: Drug development
- Global Bisphosphonate Drug Market Survey, Latest Trends in Market and Future Forecast 2028 on February 20, 2019 at 4:10 am
The report moreover gives estimations of income and development rate grounded on each market section. To request a sample copy of this report, click the link: https://market.us/report/bisphosphonate-d... […]
- PPD and HLT to Create Data Science-Driven Clinical Research Solutions in China to Enhance Global Drug Development on February 20, 2019 at 4:00 am
Pharmaceutical Product Development, LLC (PPD) and Happy Life Tech (HLT) of China have signed an exclusive agreement to develop a distinctive service offering for the China drug-development market deli... […]
- Drug distributor McKesson seeks big warehouse expansion in Cheektowaga on February 20, 2019 at 3:39 am
McKesson Corp. is seeking $1.24 million in sales tax breaks on new equipment from the Erie County Industrial Development Agency to make the project competitive with an alternative site in southern ... […]
- Fast track for AbbVie drug • Zell bets on health tech • Sterigenics sues Illinois EPA on February 20, 2019 at 3:15 am
FDA TO GIVE ABBVIE ARTHRITIS DRUG PRIORITY REVIEW: North Chicago-based AbbVie said ... In a statement, Covera said it plans to use the money to finance research and development efforts in quality anal... […]
- Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects on February 20, 2019 at 1:03 am
A company may launch an authorized generic, giving them exclusivity of several months over other generic versions of the same drug. Although development of biosimilars is complex, a few companies ... […]
- Drug pricing bills in Oregon Legislature get first hearing on February 20, 2019 at 12:14 am
That bill requires drug companies to file an annual report on drug prices and the cost of research, development and marketing of drugs to the Department of Consumer and Business Services. Eric Lutt, s... […]
- Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology on February 19, 2019 at 6:35 am
The signal transducer and activator of transcription (STAT) are transcription factors that work via JAK/STAT pathway regulating the expression of genes involved in cell survival, proliferation, differ... […]
- The 100 Leading Pioneers Of AI Drug Development on February 13, 2019 at 12:48 pm
Deep Knowledge Analytics picked the 'Top 100 AI Leaders in Drug Discovery and Advanced Healthcare’ out of an initial pool of 500 outstanding candidates. Unless a new AI winter wind blows and sweeps ov... […]
- New FDA Program Aims to Improve Quality, Innovation in Drug Development on February 13, 2019 at 9:57 am
The FDA is taking steps toward improving the quality of drug manufacturing while promoting innovation through a newly-released draft guidance, according to a press release. According to FDA Commission... […]
via Bing News